Invited Review

Aminoacyl-tRNA synthetases as drug targets in eukaryotic parasites

James S. Pham, Karen L. Dawson, Katherine E. Jackson, Erin E. Lim, Charisse Flerida A. Pasaje, Kelsey E.C. Turner, Stuart A. Ralph

Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Victoria 3010, Australia

A B S T R A C T

Aminoacyl-tRNA synthetases are central enzymes in protein translation, providing the charged tRNAs needed for appropriate construction of peptide chains. These enzymes have long been pursued as drug targets in bacteria and fungi, but the past decade has seen considerable research on aminoacyl-tRNA synthetases in eukaryotic parasites. Existing inhibitors of bacterial tRNA synthetases have been adapted for parasite use, novel inhibitors have been developed against parasite enzymes, and tRNA synthetases have been identified as the targets for compounds in use or development as antiparasitic drugs. Crystal structures have now been solved for many parasite tRNA synthetases, and opportunities for selective inhibition are becoming apparent. For different biological reasons, tRNA synthetases appear to be promising drug targets against parasites as diverse as Plasmodium (causative agent of malaria), Brugia (causative agent of lymphatic filariasis), and Trypanosoma (causative agents of Chagas disease and human African trypanosomiasis). Here we review recent developments in drug discovery and target characterisation for parasite aminoacyl-tRNA synthetases.

© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

Contents

1. Introduction – the need for new antiparasitic drugs .......................................................... 2
2. Protein translation as a drug target .................................................................................... 2
3. Aminoacyl-tRNA synthetases as drug targets ................................................................. 3
4. Existing aARS inhibitors in parasites ................................................................................ 6
4.1. Alanyl-tRNA synthetase .............................................................................................. 6
4.2. Asparaginyl-tRNA synthetase ..................................................................................... 6
4.3. Isoleucyl-tRNA synthetase ......................................................................................... 7
4.4. Leucyl-tRNA synthetase ............................................................................................. 7
4.5. Lysyl-tRNA synthetase ............................................................................................... 7
4.6. Methionyl-tRNA synthetase ....................................................................................... 8
4.7. Prolyl-tRNA synthetase ............................................................................................. 8
4.8. Threonyl-tRNA synthetase ......................................................................................... 9
4.9. Tryptophanyl-tRNA synthetase .................................................................................. 9
4.10. Tyrosyl-tRNA synthetase ......................................................................................... 9
5. Concluding remarks ........................................................................................................ 9
Conflicts of interest ............................................................................................................. 10
Acknowledgements ........................................................................................................... 10
References .......................................................................................................................... 10

* Corresponding author. Tel.: +61 3 8344 2284.
E-mail addresses: j.s.pham@student.unimelb.edu.au (J.S. Pham), k.dawson@unimelb.edu.au (K.L. Dawson), k.putnam@unimelb.edu.au (K.E. Jackson), e.el@unimelb.edu.au (E.E. Lim), c.pasaje@student.unimelb.edu.au (Charisse Flerida A. Pasaje), turnerke@unimelb.edu.au (K.E.C. Turner), saralph@unimelb.edu.au (S.A. Ralph).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

1 Charisse Flerida is a double name.
1. Introduction – the need for new antiparasitic drugs

The prevalence and persistence of parasitic infections are both remarkable and troubling phenomena. Approximately one billion people harbour at least one worm infection (nematodes and platyhelminths) (Lustigman et al., 2012) and many individuals are simultaneously infected with multiple parasites from distantly related eukaryotic phyla (Fever et al., 2008; Gething et al., 2011; Nacher, 2012). These parasites cause diseases that impose a serious burden to the health and economic development of affected countries, and are therefore the subject of many varied prevention and control strategies. No human-licensed vaccine exists for any eukaryotic disease, therefore drugs are a major component of intervention against most parasitic diseases (Prichard et al., 2012). Drug-based strategies for treatment of verified infections, mass drug administration to presumptive infected communities or at risk individuals (e.g. pregnant mothers), and sporadic prophylaxis for individuals. In many cases existing drug-based programs are at risk from parasites developing resistance, and therefore rendering ineffective our affordable and effective drugs. Some antiparasitic drugs have already had their effective usage severely restricted in regions due to the development of widespread drug resistance (Baird, 2005; Croft and Olliaro, 2011). The development of future control strategies is threatened by the impending and inevitable emergence of resistance to additional drugs (Geerts and Gryseels, 2000). To deal with existing and future shortcomings of antiparasitic drugs, multiple classes of new drugs are urgently needed for many parasitic diseases.

Parasites cause diverse types of disease, requiring drug treatments that address varying causes of pathogenesis. Apicomplexan parasites include Plasmodium spp., Toxoplasma gondii and Cryptosporidium. All parasites in this phylum are obligate intracellular parasites, but their host range and disease type vary immensely. Plasmodium species cause generally acute disease through proliferation within and destruction of erythrocytes. Most existing anti-malarial drugs work by killing this proliferative intra-erythrocytic stage, though action against the parasite forms that initially infect humans (sporozoites) and the forms that are transmitted to mosquitoes (gametocytes) is highly desirable in addition to disease control purposes (Burrows et al., 2013). Toxoplasma gondii parasites infect many diverse animals and many cell types. In humans, Toxoplasma is normally pathogenic only in immunocompromised individuals or in the human foetus. Drugs are needed to arrest the faster growing tachyzoite stages of Toxoplasma, as well as the latent bradyzoite stages that form cysts in the brain and other organs (Rodriguez and Szajman, 2012). Cryptosporidium infects epithelial cells of the intestine, causing potentially severe and chronic diarrhoea. As with Toxoplasma, the most severe Cryptosporidium cases are in immunocompromised individuals, and the need for drugs is more pressing for treatment of such cases (Rossignol, 2010).

Trypanosomatid parasites also cause a broad spectrum of diseases. Trypanosoma brucei, spread by the bite of the tsetse fly, causes human African trypanosomiasis, also known as sleeping sickness. These parasites proliferate extra-cellularly in the bloodstream and lymphatic system and later infect the central nervous system (CNS) (Barrett et al., 2007). This disease is fatal within months to years if not treated, and most existing treatments are difficult to administer, toxic or ineffective. New drugs must overcome the additional challenge of crossing the blood brain barrier to treat parasites in the CNS. Trypanosoma cruzi infections are the cause of the chronic and potentially fatal Chagas disease. Existing drugs to treat T. cruzi are ineffective if not administered early during infection and are highly toxic. Leishmania, the second medically important genus of trypanosomatid parasites, includes species that also cause a range of serious human diseases. In humans, Leishmania parasites invade and grow within phagocytic cells. As with other trypanosomatid parasites, existing drugs are generally toxic, difficult to deliver and subject to parasite resistance (Stuart et al., 2008). Although trypanosomatid parasites kill fewer people than malaria, the lack of effective and safe drugs arguably makes discovery of new drugs even more pressing for these parasites.

Three parasites whose anaerobic metabolism distinguishes them from most other eukaryotes are the extracellular parasites Giardia, Trichomonas, and Entamoeba. In these parasites the mainstays for treatment are the nitroimidazole drugs, which are activated by the parasites’ unusual pyruvate:ferredoxin oxidoreductase enzymes (Ali and Nozaki, 2007). In each of these parasites, resistance to nitroimidazol is possible through altered metabolism and alternative drugs are scarce or ineffective (Upcroft and Upcroft, 2001).

The final parasite discussed below in the context of tRNA synthetase targets is the helminth parasite Brugia. Brugia malayi is a nematode spread between humans by mosquitoes and is one of several parasites to cause human filariasis. Lymphatic filariasis is caused by immunological reaction to the adult worms and the thousands of transmissive microfilaria they produce. Drug discovery against nematodes introduces the added difficulty of selective inhibition between the bilaterian animal parasites and their hosts, although Brugia’s dependence on its bacterial Wolbachia symbiont may offer other potential drug targets (Bandi et al., 2001).

2. Protein translation as a drug target

One biological pathway that has been thoroughly validated as a target for anti-infective compounds in a wide range of microbes is the process of protein translation. Most antibiotics that target protein translation interact with microbial ribosomes themselves—binding directly to the rRNA or ribosomal subunit proteins. However, additional molecules within the broader process of protein translation can act as targets for drugs. One such target for existing and future antimicrobial therapeutics is the aminoacyl-tRNA synthetase (aaRS) family. This family of enzymes catalyses the attachment of amino acids to their cognate tRNAs to produce the aminoacyl tRNAs (also aa-tRNA or charged tRNA) that are the substrates for translation (reviewed by Ibba and Soll, 2000). The aaRSs enzymes are not only responsible for producing the raw materials for translation, but also for ensuring the fidelity of translation from nucleic acid to amino acid information. Disruption of aaRSs therefore interrupts or poisons the process of protein translation. Compounds that inhibit aaRSs have been successfully exploited, with at least one antibacterial drug, mupirocin, currently in clinical use for the topical treatment of Staphylococcus aureus, that acts through the inhibition of the isoleucyl-tRNA synthetase (IleRS) of gram-positive bacteria (Nakama et al., 2001). The pursuit of diverse other aminoacyl-tRNA synthetases has yielded specific aaRS inhibitors (Rock et al., 2007), some of which are currently in clinical trials as antimicrobials (de Jonge et al., 2006; Koon et al., 2011).
of housekeeping functions, such as the block of gene expression by rifampicin, has been successfully exploited for slow-growing microbes such as latent stage *Mycobacterium tuberculosis* (Leung et al., 2011). A second aspect of parasite protein translation that renders it a plausible drug target is the immense evolutionary distance between this process in some parasites and human hosts. Furthermore, several parasites have bacterial-like protein translation pathways that are not shared by humans. Apicomplexan parasites in particular, are dependent on their relict plastid (apicoplast), which retains much of the cyanobacterial protein translation apparatus of plastids’ ancestor (Jackson et al., 2011). Trypanosomatid parasites are highly dependent on protein translation in their unusual kinetoplastid mitochondrion, and the protein translation therein differs in several aspects from the translation found in human mitochondria or cytosol (Schneider, 2001; Niewmann et al., 2011). These examples highlight the presence of aaRSs in multiple organelles, all of which may be considered when contemplating drug targets.

A number of recent reviews have detailed drug discovery and development against bacterial and fungal aaRSs (Kim et al., 2003; Ochsner et al., 2007; Vondenhoff and Van Aerschot, 2011; Lv and Zhu, 2012). In this review we discuss prospects for antiparasitic drug development from such inhibitors for each of the tRNA synthetases.

Discrimination between different amino acids with similar chemical structures is a biochemical challenge and some aminoacyl-tRNA synthetases are prone to errors in charging. Errors can be reduced by recognition and elimination of misactivated noncognate amino acids, or through editing of misacylated tRNAs. Proof-reading is achieved both through editing domains on the aaRS enzymes themselves, as well as by stand-alone editing enzymes (Ahel et al., 2003; Sokabe et al., 2005). These domains and enzymes have the potential to act as targets for drugs, and several aaRS inhibitors are thought to act via inhibition of the editing process (Rock et al., 2007; Tan et al., 2013).

In addition to their canonical roles in tRNA aminoacylation, these ancient enzymes have also evolved extra functions, in some cases through the acquisition of novel protein domains (Lee et al., 2004; Smirnova et al., 2012; Guo and Schimmel, 2013). In eukaryotes in particular, tRNA synthetases also play roles in non-translation processes including the regulation of transcription, RNA splicing, apoptosis, angiogenesis, immune responses and signalling events. These moonlighting functions may be crucial in some organisms, and some inhibitors that focus specifically on these non-protein-translation roles of aaRSs have been explored. Non-canonical roles have been suggested for several parasite tRNA syn-

3. Aminoacyl-tRNA synthetases as drug targets

Before considering specific parasite targets, let us briefly consider what types of activities might be inhibited when focusing on aaRSs. Aminoacyl-tRNA synthetases catalyse a two-step reaction whereby an ATP and amino acid molecule (AA) enter the active site, forming an aminoacyl-adenylate intermediate (1), followed by the esterification of the amino acid to the 3’ end of the tRNA, forming the final ‘charged’ aminoacyl-tRNA (2).

\[
\text{AA + ATP + AARS} \rightarrow \text{AARS \cdot AA-AMP + PPi} \quad (1)
\]

\[
\text{AARS \cdot AA-AMP + tRNA} \rightarrow \text{AARS + AA-tRNA + AMP} \quad (2)
\]

This presents several sites on aaRS enzymes that may be considered for drugging purposes; a binding site for ATP, an adjacent amino acid binding site, and a fold for tRNA recognition and binding (Fig. 1). Most aaRS inhibitors bind to the ATP and amino acid binding sites, in many cases as analogues of ATP, amino acids, or aminoacyl-adenylate intermediates (Vondenhoff and Van Aerschot, 2011). Below we review prospects for antiparasitic drug development from such inhibitors for each of the tRNA synthetases.

Discrimination between different amino acids with similar chemical structures is a biochemical challenge and some aminoacyl-tRNA synthetases are prone to errors in charging. Errors can be reduced by recognition and elimination of misactivated noncognate amino acids, or through editing of misacylated tRNAs. Proof-reading is achieved both through editing domains on the aaRS enzymes themselves, as well as by stand-alone editing enzymes (Ahel et al., 2003; Sokabe et al., 2005). These domains and enzymes have the potential to act as targets for drugs, and several aaRS inhibitors are thought to act via inhibition of the editing process (Rock et al., 2007; Tan et al., 2013).

In addition to their canonical roles in tRNA aminoacylation, these ancient enzymes have also evolved extra functions, in some cases through the acquisition of novel protein domains (Lee et al., 2004; Smirnova et al., 2012; Guo and Schimmel, 2013). In eukaryotes in particular, tRNA synthetases also play roles in non-translation processes including the regulation of transcription, RNA splicing, apoptosis, angiogenesis, immune responses and signalling events. These moonlighting functions may be crucial in some organisms, and some inhibitors that focus specifically on these non-protein-translation roles of aaRSs have been explored. Non-canonical roles have been suggested for several parasite tRNA syn-

![Fig. 1. Schematic representation of an aminoacyl-tRNA synthetase. Various aaRS domains are illustrated: the editing domain (red); catalytic domain (cyan); anticodon-binding domain (indigo); and parasite-specific domains (purple). Possible sites of interaction between aaRS and compound (with existing examples) are indicated by numbers: editing site (1); active site (2); allosteric sites (3); parasite-specific domains (4); and anticodon-binding site (5). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](image-url)
Table 1
Representative inhibitors of aminoacyl tRNA synthetases in parasites and other infectious agents. The names of the structures shown are indicated in bold text. Structures are derived from PubChem, Chemspider or redrawn from original papers.

<table>
<thead>
<tr>
<th>Target</th>
<th>Compound name</th>
<th>Comments</th>
<th>References</th>
<th>Structure</th>
<th>Parasite</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>AlaRS</td>
<td>A3; A5</td>
<td>In silico docking against the P. falciparum AlaRS identified several compounds that inhibited parasite growth in culture</td>
<td>(Khan et al., 2011)</td>
<td>Plasmodium falciparum</td>
<td>Active site*</td>
<td></td>
</tr>
<tr>
<td>AsnRS</td>
<td>Variolin B, Rishirilide B, Cycloadenosine, Phenanthridinol, Phenanthrylethanone, Dimethylmalonamidine</td>
<td>Compounds identified from in silico screen against the Brugia malayi AsnRS protein structure identified some that inhibited BmAsnRS in a pretransfer assay. Some compounds with selectivity compared to human AsnRS.</td>
<td>(Sukuru et al., 2006)</td>
<td>Brugia malayi</td>
<td>Active site*</td>
<td></td>
</tr>
<tr>
<td>AsnRS</td>
<td>Natural product extracts (199 in total) (L-aspartate-β-hydroxamate)</td>
<td>Natural product extracts inhibit the pre-transfer editing of the Brugia malayi AsnRS. Established a pre-transfer editing assay using malachite green.</td>
<td>(Danel et al., 2011)</td>
<td>Brugia malayi</td>
<td>Pre-transfer editing site*</td>
<td></td>
</tr>
<tr>
<td>AsnRS</td>
<td>Tamandamycins (TAM) A; TAM B; TAM E; TAM F; TAM G</td>
<td>Natural compounds isolated from Streptomyces sp. 17944 extracts. TAM B was the most potent with an IC50 of 30 µM against BmAsnRS and killed adult worms in culture.</td>
<td>(Yu et al., 2011)</td>
<td>Brugia malayi</td>
<td>Pre-transfer editing site*</td>
<td></td>
</tr>
<tr>
<td>AsnRS</td>
<td>WS9326A (1); WS9326C (2); WS9326D (3); WS9326E (4)</td>
<td>Natural compounds isolated from Streptomyces sp. 9078. WS9326D inhibits Brugia AsnRS activity, kills adult B. malayi parasites in culture, and has low cytotoxic to human hepatic cells.</td>
<td>(Yu et al., 2012)</td>
<td>Brugia malayi</td>
<td>Pre-transfer editing site*</td>
<td></td>
</tr>
<tr>
<td>IleRS</td>
<td>Mupirocin (pseudomonic acid)</td>
<td>Kills ex vivo cultured Plasmodium falciparum; delayed death phenotype. Mupirocin is clinically used for topical treatment of bacterial skin infections</td>
<td>(Istvan et al., 2011)</td>
<td>Plasmodium falciparum</td>
<td>Active site</td>
<td></td>
</tr>
<tr>
<td>IleRS</td>
<td>4-Thiaisoleucine</td>
<td>Isoleucine analogue, competitive inhibitor of cytosolic IleRS. Inhibits growth of in vitro Plasmodium parasites at micromolar concentrations.</td>
<td>(Istvan et al., 2011; Liu et al., 2006)</td>
<td>Plasmodium falciparum</td>
<td>Active site*</td>
<td></td>
</tr>
<tr>
<td>IleRS</td>
<td>Ile-AMP analogues (21 in total) — NSC70422 shown</td>
<td>Inhibits growth of T. brucei bloodstream forms. Selective compared to mammalian cells.</td>
<td>(Cestari and Stuart, 2013)</td>
<td>Trypanosoma brucei</td>
<td>Active site*</td>
<td></td>
</tr>
</tbody>
</table>
Benzoxaborole derivatives (26 shown) Compounds inhibit aminoacylation by TbLeuRS and growth of *T. brucei* bloodstream forms in culture. Low mammalian cell cytotoxicity. (Ding et al., 2011) 

2-Pyrrolinone derivatives (8 shown) Virtual screening approach with *in silico* docking and pharmacophore to guide compound synthesis. Compounds inhibited in TbLeuRS activity in mid-micromolar range. (Zhao et al., 2012) 

N-(4-sulfamoylphenyl) thioureas derivatives (59 shown) Inhibited TbLeuRS at low micromolar concentrations with moderate selectivity compared to human cytoplasmic LeuRS. Compounds showed poor permeability and did not inhibit *T. brucei* growth in culture. (Zhang et al., 2003) 

LysRS Cladosporin Inhibit blood and liver proliferation of *P. falciparum* at the nanomolar range through interaction with the cytoplasmic LysRS. Selectivity for PfLysRS compared to human LysRS. (Hoepfner et al., 2012) 

Aminoquinolone derivatives (21 in total series); benzimidazoles; 2-amino-8-hydroxyquinoline (1312 shown) Compounds selectively inhibit TbMetRS and the growth of bloodstream form *T. brucei* in culture. Low toxicity for mammalian cells. Compounds suppress parasitaemia in a mouse model but not curative. (Shibata et al., 2011) 

Urea-based inhibitors series (26 shown) Selective inhibitors of TbMetRS compared to human MetRS and inhibited *T. brucei* growth in culture. Compounds were cell-permeable, had good pharmacokinetics and low cytotoxicity against mammalian cells. (Shibata et al., 2012) 

MetRS REP8839 Potent bacteriostatic activity against *S. aureus* and various other gram-positive bacteria. Currently being evaluated for topical treatment for *S. aureus* infections. (Critchley et al., 2005)
A novel diaryldiamine that displays antimicrobial activity to a spectrum of clinically important gram-positive. Inhibits toxin production and sporulation of C. difficile in vitro. (Crichtley et al., 2009)

**MetRS** REP3123

Febrifugine derivative: nanomolar inhibitor of sporozoite propagation in ex vivo hepatocytes and cultured *P. falciparum* in erythrocytes. HF inhibition is ATP-dependent. Phase II clinical trials for cancer/fibrosis - Antimalarial in vivo mouse studies. (Keller et al., 2012; Zhou et al., 2013)

**ProRS** Halofuginone (HF)

Specific inhibitor of fungal ThrRS. Kills *ex vivo* cultured *Plasmodium falciparum*, cures mice of *P. yoelii*. Rapid death phenotype in blood stage parasites. (Otroguro et al., 2003)

**ThrRS** Borrelidin

Specific inhibitor of fungal ThrRS. Kills *ex vivo* cultured *Plasmodium falciparum*, cures mice of *P. yoelii*. Rapid death phenotype in blood stage parasites. (Sugawara et al., 2013)

**ThrRS analogues**

Compounds tested against cultured *P. falciparum*. All displayed >100µM IC<sub>50</sub>. (Khan et al., 2011)

**ThrRS**

Kills *Plasmodium falciparum* blood stages (K1 and FCR3 strains) in culture. Reduced cytotoxicity against human cells compared to borrelidin. (Sugawara et al., 2013)

**ThrRS**

See above.

**Active site**

Active site:

(1) proline binding pocket; (2) 3′ end tRNA binding site

Alanyl-tRNA synthetase (AlaRS) has been a focus of extensive research due to the presence of an unusual secondary catalytic site with editing activity (Guo et al., 2009; Sokabe et al., 2009). Glycine and serine are common misacylations of tRNA<sub>Ala</sub> and AlaRS enzymes can edit these products of misacylation to ensure they do not accumulate to toxic levels. Mice with defects in tRNA<sub>Ala</sub> editing have a neurodegeneration phenotype, reinforcing the importance of editing activity (Lee et al., 2006). An AlaX domain found on additional proteins is also involved in the elimination of mischarged tRNA<sub>Ala</sub> and an AlaX domain has been reported in *Plasmodium*, fused to another tRNA synthetase; PfTprRS (Khan et al., 2013b). AlaRS has also been characterised in *Plasmodium* parasites—only one version of this enzyme is encoded by the *Plasmodium* genome, despite apparent requirements for cytosolic organellar translation. As with the PfGlyRS and PfThrRS, this enzyme is post-translationally targeted to both the *Plasmodium falciparum* cytosol and the apicoplast, possibly by production of alternatively initiated proteins (Khan et al., 2011; Jackson et al., 2012). Khan et al. (2011) screened several putative inhibitors of the PfAlaRS based on *in silico* docking against structural homology models. One of these, 4-[2-nitro-1-propenyl]-1,2-benzenediol (Table 1), inhibited parasite growth at low micromolar inhibition, and produced only limited mammalian cytotoxicity at similar concentrations (Khan et al., 2011). Although it is not yet known if these compounds inhibit the parasite PfAlaRS, the dependence of cytosolic and apicoplast translation on this dual targeted enzyme makes it a conceptually attractive target.

### 4.2. Asparaginyl-tRNA synthetase

The cytoplasmic asparaginyl-tRNA synthetase (AsnRS) has been a long-standing drug target in *Brugia malayi*, a nematode that is one of the causative agents of lymphatic filariasis. This enzyme is highly expressed compared to other *Brugia* aaRSs, and, like other aaRSs mentioned above, appears to have developed non-protein-translation functions in addition to its canonical role. In *Bruga*, the AsnRS is an immunodominant antigen in human infections (Kron et al., 1995) additionally this enzyme catalyses the production of diadenosine triphosphate (Kron et al., 2003) and exhibits immunomodulatory functions associated with inflammation during host infection (Ramirez et al., 2006; Kron et al., 2012, 2013). Because of these apparently key roles, several drug discovery (and diagnostic) projects have focused on this *B. malayi* enzyme.

Two distinct strategies have been employed to find inhibitors of the *B. malayi* enzyme; *in silico* docking and high throughput screening. In the first approach, compounds from publicly available collections were docked against the *B. malayi* AsnRS (BmAsnRS). From this docking, 45 compounds were tested for their inhibition of the BmAsnRS, as assayed by a modified malachite green assay, which provides a readout for the first step in aminoacylation reaction. Of the compounds screened, a handful inhibited AsnRS aminoacylation at mid-micromolar IC<sub>50</sub> (Table 1) (Sukuru et al., 2006). Subsequent publication of a more detailed structure for the *Brugia* AsnRS in complex with a substrate analogue that acts...
as a competitive inhibitor (Crepin et al., 2011) may provide additional information to refine future docking experiments or to rationally improve existing inhibitors.

A second approach makes use of an assay that focuses on AsnRS’s capacity to recognise and edit misacylation prior to transfer. This pre-transfer editing assay initially identified compounds that promoted the editing activity of BmAsnRS, as well as allowing screening of inhibitors that blocked the BmAsnRS (Table 1) (Danel et al., 2011). The assay was then used to experimentally screen for inhibitors of BmAsnRS among tens of thousands of extracts from diverse microbial strains. Further purification and fractionation of these extracts has led to the discovery of two different compound classes—the Tirandamycins (Yu et al., 2011) and the WS9326A derivatives (Yu et al., 2012) (see Table 1)—that each inhibit BmAsnRS aminoacylation and kill adult B. malayi. Both classes appear to show some selectivity for Brugia compared to human AsnRS. Further optimisation and validation of these inhibitors is reportedly underway (Yu et al., 2011; Rateb et al., 2013).

4.3. Isoleucyl-tRNA synthetase

The protist parasite, Trypanosoma brucei, is the causative agent of human African trypanosomiasis. There is an urgent need for new, more effective, non-toxic, and cheap antitrypanosomal drugs (Fevre et al., 2008). Recent research validates the Trypanosoma brucei isoleucyl-tRNA synthetase (IleRS) as a potential drug target, with ex vivo and in vivo RNAi knockdowns showing IleRS to be essential for Trypanosoma brucei growth (Cestari and Stuart, 2013). Cestari and Stuart screened 20 compounds from the National Cancer Institute database that were structurally similar to Ile-AMP (the reaction intermediate) for killing of T. brucei bloodstream forms. Several active compounds from this screen, including NSC70442 specifically inhibited activity of recombinant T. brucei isoleucyl-tRNA synthetase (IleRS) and have good selectivity against mammalian cell lines (Table 1). Furthermore, a transgenic T. brucei line that overexpressed IleRS showed reduced sensitivity to NSC70442 and other Ile-AMP analogues, supporting IleRS as the target of these inhibitors. NSC70442 cured in T. brucei-infected mice at low mammalian toxicity (Cestari and Stuart, 2013). There is also evidence that compounds from this chemical class are able to cross the blood brain barrier (Cestari and Stuart, 2013), which is an important characteristic for antitrypanosomal drugs that can treat stage 2 trypanosomiasis (Rottenberg et al., 2005).

The most widely-used drug that inhibits aminoacyl-tRNA synthetases targets IleRS. Mupirocin (also known as pseudomonic acid, and marketed as Bactroban®), is used for the topical treatment of Staphylococcus aureus. Crystal structures of mupirocin-bound IleRS indicate that mupirocin inhibits bacterial IleRS by blocking the binding of the Ile-AMP intermediate (Nakama et al., 2001). Mupirocin has now been shown to inhibit bloodstream P. falciparum growth in the nanomolar range (Table 1) (Istvan et al., 2011). Mupirocin resistant Plasmodium parasites have mutations in the apicoplast-located IleRS, indicating that the bacterial type apicoplast IleRS is the target of mupirocin (Istvan et al., 2011). This is supported by specific defects in apicoplast morphology and segregation upon mupirocin, and in the “delayed-death” type mupirocin killing of ex vivo cultured parasites (Jackson et al., 2012), which is characteristic of inhibitors blocking apicoplast maintenance. Mupirocin failed to protect mice from a Plasmodium berghei infection, a likely result of the compound’s well known in vivo instability and its high binding to serum (Casewell and Hill, 1987). Mupirocin itself is therefore very unlikely to serve as a good lead for antiparasitic drug development, but does validate the apicoplast IleRS as a target for specific antimalarial drug research. Istvan and colleagues (Istvan et al., 2011) also showed that the Plasmodium cytosolic IleRS was inhibited by the isoleucine analogue thiaisoleucine (Table 1), which rapidly killed ex vivo cultured parasites. Thiaisoleucine also inhibits mammalian IleRS but its inhibition of Plasmodium growth supports the Plasmodium cytosolic IleRS enzyme as a potential drug target. Another inhibitor of eukaryotic IleRSs, the cyclic beta amino acid, icofungipen, shows good activity against pathogenic fungi, and has been through phase II human trials (Hasenoehrl et al., 2006). We are unaware of any tests on the activity of icofungipen in any parasite.

4.4. Leucyl-tRNA synthetase

LeuRS is a proofreading aaRS that is inhibited by 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) by trapping tRNAexo in the editing site (Rock et al., 2007). AN2690 has potent antifungal activity, and was reported to be undergoing clinical trials (Seiradake et al., 2009). Inspired by this success story, inhibitors based on the benzoxaborole core—that contains a boronic acid and forms an adduct with the tRNA—were explored as LeuRS inhibitors for T. brucei. For this purpose, a homology model of the T. brucei CP1 (editing) domain based on the solved Candida albicans LeuRS was used to design a series of benzoxaborole compounds (Ding et al., 2011). Structure–activity relationship was studied, and the best of the compounds (Table 1) inhibited TbLeuRS aminoacylation and T. brucei ex vivo growth at low micromolar IC50s, with low mammalian cell toxicity (Ding et al., 2011). A subsequent TbLeuRS study (Zhao et al., 2012), used a homology model based on the solved Pyrococcus horikoshii LeuRS structure (Fukunaga and Yokoyama, 2005) and instead targeted the enzyme’s synthetic site. This study performed in silico screening with the SPECS chemical library, and tested a range of compounds with a 2-pyrolinone scaffold against an in vitro TbLeuRS aminoacylation assay. Though a diverse group of analogues showed some structure–activity relationship, inhibition occurred only at rather high concentrations, with the most potent compounds showing IC50s between ~30 and 100 μM (Table 1) (Zhao et al., 2012).

More recently, a new class of T. brucei LeuRS inhibitors, N-[4-sulfamoylphenyl]thioureas, which targets the synthetic catalytic site, has been discovered through the screening and modification of a small, targeted library of putative aaRS inhibitors (Zhang et al., 2013). This class of inhibitors are designed to inhibit by mimicking the intermediate product, aminoacyl-AMP. To further improve upon the activities of the compounds, TbLeuRS was used to dock inhibitors and guide synthesis of derivatives. The best compound, 59, showed an IC50 of 1.1 μM and is predicted to form four hydrogen bonds and favourable hydrophobic interactions with the synthetic enzyme pocket. These compounds exhibited moderate selectivity (4.5–7.3 fold) compared to human cytoplasmic LeuRS, but none of the compounds optimised for inhibition of the synthetic site inhibited growth of T. brucei in culture at 100 μM (Table 1). Experiments using caco-2 cell permeability assays indicated that these compounds have poor permeability and may explain the poor inhibition seen in the ex vivo bioassays. This new inhibitor class shows early promise as TbLeuRS inhibitors but will require more work to address permeability issues and demonstrate the ability to kill parasites and cure mice infections.

4.5. Lysyl-tRNA synthetase

In a recent comprehensive study, the fungal secondary metabolite cladosporin (Table 1) was shown to inhibit blood and liver proliferation of P. falciparum at the nanomolar range (Hoepfner et al., 2012). Studies in fungi showed that heterozy-
gote mutants of LysRS were more sensitive to cladosporin, and fungi with separate point mutations in LysRS were more resistant to cladosporin. Plasmodium parasites overexpressing the cytosolic PfLysRS are similarly more resistant to cladosporin. In silico docking suggests that cladosporin interacts with the ATP-binding pocket of the LysRS and increasing concentration of ATP in vivo significantly reduced inhibition, consistent with this in silico prediction. Cladosporin only demonstrated weak inhibition of recombinant human LysRS at high micromolar concentrations, which was postulated to be due to steric hindrance within the ATP-binding pocket (Hoepfner et al., 2012). The crystal structure of the cytoplasmic PfLysRS was subsequently solved, and confirms a structural difference in this region is likely to be the basis for this selectivity (Khan et al., 2013a). The structure also describes additional differences that may allow for the design of selective inhibitors that act against the Plasmodium but not human LysRS (Khan et al., 2013a).

Whilst cladosporin inhibits the Plasmodium cytosolic LysRS, Hoen and colleagues (Hoen et al., 2013) have pursued the apicoplast PfLysRS isoform as a potential drug target. They constructed a virtual lysyl-adenylate mimic compound library and screened this through in silico docking against a homology model of P. falciparum apicoplast LysRS. Two of the tested compounds (M-26 and M-37), had potent delayed death inhibition (consistent with apicoplast-specific activity) and inhibited aminoacylation by recombinant apicoplast PfLysRS (Table 1) (Hoen et al., 2013). The availability of specific inhibitors for both the cytoplasmic and apicoplast LysRS provides ideal tools for studying the relative importance of organellar and cytosolic tRNA synthetases as well as providing promising drug leads. Cladosporin itself possesses poor oral bioavailability and seems therefore to be a poor drug candidate itself (Hoepfner et al., 2012), but may serve as a chemical starting point for other PfLysRS inhibitors.

4.6. Methionyl-tRNA synthetase

One series of compounds that has been investigated as antitrypanosomal agents was inspired by the success of the bacterial MetRS diaryl diamines inhibitors (Table 1) (Critchley et al., 2009). These bacterial inhibitors are highly selective for bacterial versus mammalian enzymes. Some of these compounds do inhibit recombinant human mitochondrial MetRS, however no cytotoxicity of mammalian cell cultures is apparent (Green et al., 2009). Homology models based on several MetRS structures were used to guide synthesis of related T. brucei MetRS inhibitors (Table 1), and these were tested for binding to TbMetRS (Shibata et al., 2011). Inhibition of aminoacylation activity was assayed at 50 nM and the most interesting of compounds showed >95% inhibition of activity at this concentration. Compounds were also screened using ex vivo cultures of T. brucei (and Trypanosoma cruzi) and the most effective, compound 1, had an EC50 of 4 nM and low toxicity for mammalian cells. Compound 1 was delivered at 25 mg/kg/day for 3 days using subcutaneous osmotic minipump to circumvent issues with bioavailability, and showed initial suppression of parasitaemia but mice later succumbed to disease (Shibata et al., 2011). Partial knockdown of the T. brucei MetRS through RNAi produced a severe growth defect, confirming the importance of this enzyme (Shibata et al., 2011).

Two subsequent studies characterised structures of the Leishmania MetRS (Larson et al., 2011b) and the TbMetRS (Koh et al., 2012) bound to substrates, Met, MetAMP and, in the case of the TbMetRS, inhibitors. This study revealed extensive conformational rearrangement by the TbMetRS structure upon inhibitor binding, suggesting conformation selection as the basis for binding (Koh et al., 2012). Inspection of the structures showed extensive rearrangement of the conformations occurred with introduction of inhibitors—with the compound occupying a pocket that was not present with substrates Met or MetAMP—called the auxiliary pocket. The crystal structure of ligand-free TbMetRS1 is very similar to the inhibitor-bound conformation of TbMetRS and supports the idea that conformational selection is the likely model for binding of inhibitors to TbMetRS (Koh et al., 2012). The LmMetRS structure additionally revealed several differences from its human homolog near the active site that might be exploited with inhibitors that could specifically target the parasite enzyme ( Larson et al., 2011b).

To improve upon the earlier MetRS inhibitors that exhibited poor PK profiles and poor bioavailability (Jarvest et al., 2002, 2003), the authors made a follow up compound series (Table 1) ( Shibata et al., 2012). Guided by structures of inhibitor-bound MetRS, it was rationalised that a urea-based scaffold would increase bioavailability. The enzymes were screened using a thermal shift binding assay then used in vitro aminoacylation assays to test for inhibition of TbMetRS and HsMitoMetRS. Compounds had similar IC50 and selectivity to the original series and improved pharmacokinetic characteristics, but unfortunately the oral bioavailability remained poor. Nonetheless these authors have demonstrated the importance of this enzyme for parasite growth, as well as the capacity to design specific inhibitors against trypanosomatid MetRS, and this remains a highly promising target.

4.7. Prolyl-tRNA synthetase

One long-used traditional antiparasitic agent, febrifugine, has recently been revealed to inhibit prolyl tRNA synthetase. Thisquinazolinone alkaloid is a constituent of the Chinese herbal medicine, Chângsàn ( Dichroa febrifuga). Despite excellent antiparasitic activity, its strong liver toxicity and gastrointestinal side effects have limited the use of febrifugine as a widespread therapeutic. Febrifugine analogues have been synthesised with a reduced capacity to form toxic intermediates and have demonstrated potent inhibition of P. falciparum isolates in ex vivo culture, P. berghei in vivo infection and impressive cure rates in an in vivo Aotus monkey model (Zhu et al., 2010, 2012). One of these analogues, the synthetic halogenated derivative halofuginone (Table 1), potently inhibits cultured erythrocytic and liver stage Plasmodium falciparum (Kobayashi et al., 1999; Derbyshire et al., 2012; Keller et al., 2012). Halofuginone has been a US FDA (Food and Drug Administration) approved drug for apicomplexan parasite (coccidia) infections of chickens and turkeys since the 1980s and is currently involved in both Stage I and Stage II clinical trials for use against proliferative diseases that include carcinoma, advanced solid tumours and AIDS related malignancies (Folz et al., 1988; Elkin et al., 1999; de Jonge et al., 2006; Koon et al., 2011).

Recent papers have demonstrated that halofuginone and other febrifugines act through inhibition of ProRS. In an elegant study, Keller et al. (2012) demonstrated first that halofuginone (which was known to activate the amino acid starvation response) inhibited an in vitro translation assay, and translation was restored only by addition of excess proline. Halofuginone also bound to and inhibited recombinant human ProRS. Addition of excess proline also reduced the sensitivity of P. falciparum parasites to halofuginone (Keller et al., 2012). A subsequent study showed that halofuginone specifically blocks the formation of the Pro-AMP adenylate complex (Zhou et al., 2013). Interestingly, the inhibition is reliant on the presence of ATP to allow high affinity binding of halofuginone to ProRS. ATP directly assists the orientation of halofuginone to enable one end to occupy the proline binding site and consequently, to competitively block activation of this amino acid, whilst the other end simultaneously mimics the 3’ end of the tRNA mol-
ecule. This ATP-dependent binding of halofuginone to ProRS has also been modelled with the *P. falciparum* ProRS, which is predicted to recapitulate these dual site enzyme inhibition interactions (Zhou et al., 2013). The apparent efficacy of febrifugines as antimalarial agents, despite their obvious inhibition of human ProRS and proliferating human cells serves as a reminder that drug selectivity for an acute parasitic infection need not necessarily rely on molecular specificity.

### 4.8. Threonyl-tRNA synthetase

Borrelidin, first isolated from *Streptomyces spp.*, acts as a non-competitive, selective inhibitor that binds to a unique hydrophobic cluster near the active site of some bacterial and eukaryotic ThrRS enzymes (Nass and Hasenbank, 1970; Ruan et al., 2005; Gao et al., 2012). Borrelidin is an inhibitor of yeast cyclin-dependent kinase (Tsuchiya et al., 2001) and an activator of pro-apoptotic mediators in endothelial cells (Kawamura et al., 2003). Several investigations on the effect of borrelidin on *Plasmodium* shine light on its presumed target PfThrRS (Table 1). Borrelidin potently inhibits parasite proliferation in culture, with an immediate effect on the first asexual erythrocytic life-cycle after treatment, typical of cytosolic inhibition. This inhibition is unlike the delayed-death seen for apicoplast inhibitors (Ishiyama et al., 2011; Jackson et al., 2012; Azcarate et al., 2013) and borrelidin does not appear to inhibit organellar division (Jackson et al., 2012). *Plasmodium* possesses only one PfThrRS, a dual-targeted enzyme, which is trafficked to the apicoplast and cytosol (Khan et al., 2011; Jackson et al., 2012). The immediate inhibition seen with Borrelidin is consistent with the requirement of this PfThrRS for cytosolic translation. Although the exact molecular mechanism responsible for the antimalarial effect of borrelidin remains unclear, raised concentrations of L-Threonine in culture reduce parasite sensitivity, thus implicating threonine utilisation and PfThrRS as likely targets of borrelidin (Ishiyama et al., 2011).

In addition to its *ex vivo* use, borrelidin has been shown to cure mice of rodent malaria infections (Otoguro et al., 2003; Azcarate et al., 2013), with one report of borrelidin-cured mice then acquiring protection from subsequent challenge by *Plasmodium yoelii* (Azcarate et al., 2013). Although, borrelidin displays some mammalian cytoxicity, there are efforts to synthesise borrelidin analogues with decreased toxicity (Wilkinson et al., 2006; Sugawara et al., 2013). More recently, Sugawara et al. (2013) generated a borrelidin-like series (Table 1) that reduced the cytoxicity whilst simultaneously increasing the antimalarial activity, an important step to further progress the development of borrelidin as a future antimalarial drug.

Khan et al. (2011) have also investigated novel inhibitors of the PfThrRS predicted by *in silico* docking of small molecule compound libraries against homology models of the PfThrRS. The best of these compounds showed only moderate inhibition (IC50 from ~75 to 150 μM) of *ex vivo* *P. falciparum* growth (Table 1) (Khan et al., 2011).

### 4.9. Tryptophanyl-tRNA synthetase

Considerable divergence in sequence and structure of TrpRSs has previously been described across the three domains of life. This has attracted some interest for TrpRS as a drug target, including in parasites. In trypanosomatid parasites this divergence is compounded by the requirement for an additional TrpRS that charges a non-canonical UGA-recognising tRNA<sup>TP</sup> required in the parasite’s mitochondria. This tRNA is encoded by the same gene as that used for cytosolic translation, but the version used in the mitochondria is first chemically altered through thiol modification and C to U nucleotide editing at the first position of the anticodon (Alfonzo et al., 1999). *T. brucei* encodes two TrpRS enzymes – one that recognises only the canonical tRNA in the cytosol, plus a second that recognises the altered tRNA in the mitochondrion (Charriere et al., 2006). This later TbTrpRS is lineage specific, and presents opportunities for selective inhibition. A similar scenario may exist in the apicoplast of apicomplexan parasites, where the UGA in the apicoplast genome also appears to be partially decoded as tryptophan rather than a stop codon (Wilson, 2002).

Structural analysis of TrpRS enzymes from various parasites also appears to offer opportunities for selective drug development. Analysis of the crystal structure of TrpRS from *Giardia lamblia* revealed a 16-residue α-helix instead of the hydrophobic β-hairpin that stabilises the bond between tryptophan and the enzyme (Arakaki et al., 2010). The *Toxoplasma* and *Trichomonas* sequences also diverge from the human sequence in this area (Arakaki et al., 2010). These are important sub-domains of the human enzyme, so these marked differences may provide a means of selectively inhibiting the parasite homologues. Additional structures for the *T. brucei* cytosolic TrpRS (Merritt et al., 2011), the *Cryptosporidium parvum* TrpRS (Merritt et al., 2011), and the *P. falciparum* TrpRS (Khan et al., 2013b; Koh et al., 2013) also reveal some additional parasite specific sub-domains or structural differences that might be exploited for drug design purposes. A structure has also been solved for a divergent member of three identified *Entamoeba histolytica* TrpRS homologues, but this enzyme lacks Trp binding and is unlikely to charge tRNA<sup>TP</sup> (Merritt et al., 2011). Although no inhibitors have thus far been reported for parasite TrpRSs, several chemical starting points exist for exploration; bacterial TrpRSs are inhibited by natural products and tryptophan analogues such as indolmycin (Rao, 1960; Kanamaru et al., 2001) and chuangxinmycin (Brown et al., 2002).

### 4.10. Tyrosyl-tRNA synthetase

To our knowledge tyrosyl-tRNA synthetases (TyrRS) have yet to be experimentally investigated as targets for drug development in parasites. However, previous studies have identified inhibitors active against bacterial TyrRS including the naturally derived 5B219383 (Berge et al., 2000; Stefanska et al., 2000; Greenwood and Gentry, 2002) and several synthetic compounds (Jarvest et al., 1999; Xiao et al., 2011a;b; Wang et al., 2013). The few parasite-specific studies on TyrRS focused on the structural aspects of the enzyme. Bhatt and colleagues (Bhatt et al., 2011), localised the cytosolic PfTyrRS to the parasite cytoplasm and noted the additional presence of PfTyrRS within infected erythrocytes. These authors also detected extracellular activity of PfTyrRS through mimicry of host cytokines to induce host immune system pro-inflammatory responses (Bhatt et al., 2011). In addition to this intriguing discovery, Bhatt et al. solved the crystal structure of PfTyrRS in complex with tyrosyl-adenylate (Bhatt et al., 2011). Structural comparisons between the *Plasmodium* and human TyrRS revealed many differences such as the organisation of loop structures and included sequence level differences at 11 residues that contribute to binding of substrate (Bhatt et al., 2011). The crystal structure of the unusual double-length TyrRS orthologue from *Leishmania major* suggest a pseudo-dimer that is formed by asymmetric domains (Larson et al., 2011a) that also differs from the host TyrRS. Taken together these differences could potentially be exploited for design of structure-based inhibitors of parasite TyrRSs.

### 5. Concluding remarks

As evident in the list of targets above, much of the research on parasite aminoacyl-tRNA synthetases has taken place over
the course of the last decade. Building on earlier studies using classical biochemistry, and a small initial number of chemical starting points, the research community is now using a myriad of technologies to investigate aaRSs and has built up an array of inhibitors that represents diverse chemical space. An encouraging development is the recent discovery of new chemicals that inhibit aaRS in eukaryotic parasites including \textit{Brugia}, \textit{Trypanosoma} and \textit{Plasmodium} parasites (Table 1). Detailed structural research has shed important light on the structural basis for aminoacylation, and provides us with insights into the number of ways in which these enzymes can be chemically inhibited. \textit{In silico} docking, rational design of compounds to fit into active sites, as well as high throughput screening have all resulted in the identification of compounds that potently inhibit aaRSs. Several combinatorial and medicinal chemistry programs have modified these starting compounds to develop compounds with acceptable pharmaceutical properties, and there are promising animal-model data for aaRS inhibitors for several parasites. Future investigations will need to consider whether these can genuinely be developed as drug like compounds, and if so, whether this can be achieved cheaply – a prime consideration for neglected parasitic diseases.

Advances across a number of systems biology platforms are accelerating the ability to make connections between inhibitors and molecular targets in parasites, and to subsequently validate these targets. Identifying resistance mutations that shed light on modes of action has been a long standing means of interrogating aaRS inhibitors. Alongside the current availability and reduced cost of next-generation sequencing technologies now means that target identification has become feasible and affordable for the larger eukaryotic parasite genomes. A number of resistance mapping studies for aaRS inhibitors in \textit{Plasmodium} set a standard for future investigations in this genre (Istvan et al., 2011; Hoepfner et al., 2012).

Two concerns, selectivity and resistance, will remain major challenges for the development of antiparasitic aaRS inhibitors. Despite these parasites being only very distantly related to each other, and cause very different diseases, they share the chemotherapeutic challenge of finding drugs that select between one eukaryote and another (humans). Selectivity is a major issue because the human genome encodes for 36 aminoacyl-tRNA synthetase, (16 cytoplasmic, 17 mitochondrial, 3 dual-targeted) (see review by Antonellis and Green (2008)) that have eukaryotic and bacterial origins (mitochondria). Avoiding inhibition of the most conserved homologs is a challenge in aaRS inhibition to avoid potential cytotoxicity. Strategies to circumvent host toxicity include exploitation of organellar, bacterial-type aaRSs where the human homologue is divergent (such as the \textit{Leishmania} AasnRS with a bacterial origin (Gowri et al., 2012)) or exploitation of parasite-specific modifications (Bour et al., 2009). It should also be kept in mind that for the protist parasites at least, they are separated by a billion years of evolution from their mammalian hosts, so molecular divergence abounds. In all of these cases, structural information is often key to identifying exploitable differences between host and parasite (Bunjun et al., 2000; Larson et al., 2011a). It is noteworthy that it is sometimes possible to design aaRS inhibitors with good selectivity even where few differences exist in active site residues between parasite and host (Shibata et al., 2011).

Resistance to antiparasitic drugs is a major concern. Eventual resistance to aaRS inhibitors is inevitable, and can only be hoped to be delayed, but this unfortunate outcome is often overlooked in the preclinical stages of drug discovery where the focus is on the optimisation of efficacy, cytotoxicity and pharmacokinetic properties. Since mupirocin, the IleRS inhibitor, was first introduced for clinical use, resistance has developed and in some cases results in mupirocin treatment failure against \textit{S. aureus} (Patel et al., 2009). Parasite drug resistance to aaRS inhibitors has been used in studies characterising aaRS inhibitors in \textit{Plasmodium} (Istvan et al., 2011) and \textit{Trypanosoma} (Ranade et al., 2013). These studies are helpful not only in informing mode of action but also useful in the prediction of development and extent of parasite drug resistance. They enable discussion of relative fitness and ultimately facilitate the design of inhibitors to which resistance is not so easily generated.

Conflicts of interest

The authors declare they have no conflicts of interest.

Acknowledgements

JSP is supported by an Australian Postgraduate Award. KEJ is supported by a CASS foundation grant. SAR is supported by an Australian Research Council Future Fellowship (FT0990350).

References


